Projected Price to Earnings: ReShape Lifesciences Inc. (RSLS)
ReShape Lifesciences develops minimally invasive anti-obesity systems where high margins are driven by unique consumables. Distribution relies on bariatric clinics, although narrow specialization creates risks due to new blockbuster drugs. The company's forward P/E ratio demonstrates valuation dynamics, where 0.00 shows the value of this parameter, helping to determine whether market expectations are justified.
Metric breakdowns and analytics for ReShape Lifesciences Inc (RSLS)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital ReShape Lifesciences|RSLS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio ReShape Lifesciences|RSLS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ReShape Lifesciences, Inc.|RSLS - Company Long-Term Liabilities|Company Short-Term Debts ReShape Lifesciences|Quick Ratio reshapelifesciences.com
- financial results and valuation multiples details:
RSLS - Company Profit|Projected Future Earnings ReShape Lifesciences|RSLS - Business Payback Period|Forward P/E Multiple ReShape Lifesciences|RSLS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ReShape Lifesciences, Inc.|RSLS - Operating profit EBITDA|Earnings per share for the last twelve months ReShape Lifesciences|RSLS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months reshapelifesciences.com|RSLS - Earnings per share increase in current year|Earnings growth forecast for next year ReShape Lifesciences
Fundamental valuation:RSLS ReShape Lifesciences Inc.
The forward P/E ratio relates the market value of ReShape Lifesciences (RSLS) to its expected earnings per share, allowing for a valuation of future revenues from minimally invasive obesity treatment technologies. An analysis of the company's current forward P/E level reveals the risk of overpaying for the brand's innovative potential, helping investors determine whether market optimism aligns with the business's actual ability to generate net income.
Competitors of ReShape Lifesciences
Forward P/E Multiple DXCM|PEN - Projected Price to Earnings Ratio|Novanta Corp - Projected Price to Earnings|Forward P/E Multiple Haemonetics Company HAE|INSP: Projected Price to Earnings|procept-biorobotics.com - Market Cap to Future Earnings Ratio|CNMD: Forward P/E Multiple|PLSE - Market Cap to Projected Earnings|INMD (InMode Corp) - Forward P/E Multiple|Projected Price to Earnings Picard Group (PMI)|Projected Price to Earnings SRDX (Surmodics, Inc.)|SENS (Senseonics Holdings, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings NeuroPace NPCE|TCMD - Projected Price to Earnings|SANUWAVE Health, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Outset Medical Corp|ELMD: Forward P/E Multiple|Price to Future Earnings Ratio LNSR|RCEL (AVITA Medical) - Forward P/E Multiple|Profound Medical Corporation (PROF) - Market Cap to Projected Earnings|Forward P/E Multiple BDMD|Projected Price to Earnings edap-tms.com EDAP|Forward P/E Multiple APYX (Apyx Medical Corporation)|Forward P/E Multiple IceCure Medical Ltd. ICCM|LUNG - Future Price to Earnings|TELA: Future Price to Earnings|CTSO (cytosorbents.com) - Projected Price to Earnings|Sensus - Future Price to Earnings Multiple|ZYXI (Zynex, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio electroCore Medical ECOR|Future Price to Earnings Vicarious Surgical Inc. (RBOT)|inspira-technologies.com (IINN) - Forward Price to Earnings Multiple|SeaStar Medical Holding Corp - Projected Price to Earnings|Forward P/E Multiple IRIDEX Corp IRIX|Intelligent Bio - Forward P/E Multiple|Market Cap to Projected Earnings Beyond Air, Inc. XAIR|Profusa (PFSA) - Future Price to Earnings|Price to Expected Earnings Ratio SSKN (STRATA Skin Sciences, Inc.)|Future Price to Earnings GlucoTrack|Projected Price to Earnings NanoVibronix Inc. (NAOV)|Forward P/E Multiple VERO|NUWE - Projected Price to Earnings Ratio|Future Price to Earnings Aethlon Medical, Inc. AEMD|ASXC: Price to Future Earnings Ratio|AVGR: Projected Price to Earnings|BioSig Technologies - Market Cap to Future Earnings Ratio|Cutera, Inc. (CUTR) - Future Price to Earnings|knowlabs.co - Future Price to Earnings Multiple|NARI (Inari Medical) - Forward P/E Multiple|Projected Price to Earnings Ratio Nevro Corp NVRO|Future Price to Earnings Silk Road Medical Inc. (SILK)
